Research Paper Volume 16, Issue 9 pp 7774—7798
The identification of a N6-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma
Figure 8. (A) Wilcoxon test compares differences in the expression of 24 widely reported WERs between different risk groups across datasets GSE32894, GSE13507, GSE48075, and TCGA-BLCA, summarizing significantly upregulated or downregulated findings with box plots. (B) ROC curves compare the performance of MPIG-derived risk scores and the expression levels of FGFR-3, PD-L1, CTLA-4, ERBB-3, HER-2, PD-1 in predicting survival shortening events in UC patients. (C) Violin plots and the Wilcoxon test compare differences in MPIG-derived risk scores between responders and non-responders to monotherapy immunotherapy (atezolizumab) in the IMvigor210 trial. (D) ROC curves and AUC values assess the performance of a binary model predicting the response of advanced UC patients to immunotherapy, based on MPIG-derived risk scores, tested in a random external dataset.